Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. - Wikidata - wikimedia - TriplyDB

Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

http://www.wikidata.org/entity/Q43215544

about

Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Mathematical modeling to characterize the inoculum effect.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Compensation of fitness costs and reversibility of antibiotic resistance mutations.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information Translational PK/PD of anti-infective therapeutics.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Current mathematical models for cancer drug discovery.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling.Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.

P2860

Q28477067-29E9C903-60CE-49B4-ACCD-1A87AD1416BA Q28550711-0167C9B6-7F25-473F-A5B4-C2A4D9A32A38 Q28601378-5657484E-418C-4322-9D20-F6D4D55332EB Q33826267-05360B8E-0F78-4331-8D30-C32BCE6104E5 Q33876563-7BD20959-F691-4009-A99C-5E2BE84D0070 Q34290045-E97B8A63-76AE-438F-9250-45DEA1EA8341 Q34737629-D1B673E8-0988-42F8-8BDC-B5FF5E9C4196 Q35168882-FF06F8B5-9DB5-4886-AB78-B86A2D070139 Q35168931-71CF05B5-3688-4124-B973-98DBAE0E799B Q35432770-CC508D25-B606-4118-8ED6-D76B2DF277C5 Q36684146-464B86E3-3939-43C5-AA54-E0884FAC4511 Q36785827-220760C3-61FF-4304-A011-F93E2ED83AD1 Q36887819-960E2A49-B15E-4025-AEDF-F001DA1D818A Q37356386-F27C68DE-5459-4ED4-A039-3C6C49CB01DC Q37538623-6E63DF48-299D-4A45-A820-7510B3DF21E1 Q37696851-D5B1A25B-1BDC-42C4-9EAE-0F95697A80F9 Q38626980-FACDBB1B-ABCE-4F98-9C9E-571A83A2CD54 Q38664871-50B3E798-CD58-4B77-8070-FEC8A78F25CC Q38853629-0C14F7CA-40D8-49FE-B7DF-91F85087ED4D Q39039505-D100A206-7326-446D-9772-D56C698AE1D8 Q39170967-F7DFE815-6C29-4DAE-BE65-B3A8C5871E75 Q39359967-387852DA-7AA4-49A7-A639-0E4DAA06105D Q39665401-B2D24B05-3A15-4A34-AF7F-F5877929FAFD Q40266214-A9533BFE-BD90-4888-A049-BD42EA9C431E Q40306198-C850ADF2-A693-468E-BDB8-1607DE5D5038 Q40375783-947A6AC4-FCF6-4ABA-AB84-B2AC4C8294FC Q40587067-61AFF64A-7BBB-4540-A09E-82CC747FE5D0 Q40657200-D9CB71E3-9B90-4B5C-8EF6-C2401BD334B6 Q40698278-B8550291-CEC1-485E-A85B-B08BC6B11546 Q41695443-F5170074-86C8-45D8-A461-4508C944C0C5 Q41987074-59CACD59-081B-440A-A2CF-C947FF994BFA Q42110580-DAD844DA-D6E9-4935-B519-63231E185FFF Q42143847-74EC135B-184F-4D20-992C-05F15661C5F9 Q42717931-3CBC485F-946C-4E77-9719-CAE310E68BB6 Q47273930-C688734E-DDDC-4212-B849-0354A1483015 Q47656109-6C53F4B8-2F03-4176-A9D1-6D61804E95FF Q47691167-086EA002-2A0A-4C1E-BDC0-727900200187 Q47897914-EF4BD150-7979-4426-A8D0-927E33E6D673 Q49792113-16132352-08F4-43BE-888D-0CCABE19DC19 Q50044377-F0B33E01-A997-44C1-A419-B3E35947C711

P2860

Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

http://www.wikidata.org/entity/Q43215544

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Development and qualification ...... gainst Pseudomonas aeruginosa.

@en

Development and qualification ...... gainst Pseudomonas aeruginosa.

@nl

type

label

Development and qualification ...... gainst Pseudomonas aeruginosa.

@en

Development and qualification ...... gainst Pseudomonas aeruginosa.

@nl

prefLabel

Development and qualification ...... gainst Pseudomonas aeruginosa.

@en

Development and qualification ...... gainst Pseudomonas aeruginosa.

@nl

P1433

Q43215544-61F7BF53-44DE-4E0A-BCBE-E6F6049E5D22

P1476

Q43215544-14CFCC3C-ECD2-4E8B-818B-7413FBF89BD3

P2093

Q43215544-079F297C-A5D4-4420-BB32-77B95373EE41

Q43215544-379C157C-2E66-44F4-ABBC-A1CF8BE2C8B3

Q43215544-48F08B1B-6F7B-4030-940A-73472E570BD0

Q43215544-855E3EE3-6D78-4E06-94CD-0F0A9FBDF8C9

P2860

Q43215544-0B5F59A6-E3FE-4D4E-AC3C-0480CA831CBE

Q43215544-0C2A98FA-5182-4688-BC21-D67C62242692

Q43215544-113B1537-3B7B-4741-8A59-57AFBEB3A434

Q43215544-25C3525E-4EA4-4147-897F-C7BA53D553F3

Q43215544-2FB18AAF-2B7D-45AF-A6F5-B63BF9010173

Q43215544-2FCFECE8-14AE-4578-9B83-FA5985A91CBE

Q43215544-3ABD5BA1-B6A0-4B21-BEF3-9B41A068CDA8

Q43215544-3CD55579-211E-477F-9EA7-B4916674FA0A

Q43215544-4DD4948C-34C1-48BE-9F38-E340240FC494

Q43215544-53494BB7-4BA1-4693-8555-60C4C23D639B

P304

Q43215544-E7458F20-47F2-41BB-9B95-6562C97860AB

P31

Q43215544-3BD06237-49AB-409D-9855-4396A5AEFE6D

P356

Q43215544-6A131C4D-5721-49A9-9120-C6833807716F

P407

Q43215544-1F7C4804-4E09-4FA8-9AAD-633738A5D2A4

P433

Q43215544-257900DB-907B-4799-B9BE-DB272FE73D74

P478

Q43215544-2B4B36D9-0C1B-43DD-BF2D-C9CD6B63DB90

P50

Q43215544-2C6C656C-2C66-4B59-B92D-B26E6A11891E

Q43215544-96202771-398F-476D-AFE6-41747C0BC4F0

P577

Q43215544-FB19F9F1-6BA8-4D5D-82FB-33A8C5F8906D

P698

Q43215544-648E29AC-20D6-4F8D-A5C7-B04BFE493C88

P921

Q43215544-6CE0212C-607A-40F5-B3A9-9B7668881AB1

P932

Q43215544-39EB4180-5BA2-4F5B-886D-60192E5DDC30

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Development and qualification ...... gainst Pseudomonas aeruginosa.

@en

P2093

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Brian T Tsuji

http://www.w3.org/2001/XMLSchema#string

Jenny C Yang

http://www.w3.org/2001/XMLSchema#string

William J Jusko

http://www.w3.org/2001/XMLSchema#string

P2860

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

Estimating data transformations in nonlinear mixed effects models.

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

Overview of nosocomial infections caused by gram-negative bacilli.

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.

Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by beta-lactams against Escherichia coli

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

P304

46-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00489-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Juergen Bulitta

P577

2008-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18852268

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

P932

2612150

http://www.w3.org/2001/XMLSchema#string